SG11201610453SA - Compounds for inhibiting hepatitis c virus, pharmaceutical compositions and uses thereof - Google Patents
Compounds for inhibiting hepatitis c virus, pharmaceutical compositions and uses thereofInfo
- Publication number
- SG11201610453SA SG11201610453SA SG11201610453SA SG11201610453SA SG11201610453SA SG 11201610453S A SG11201610453S A SG 11201610453SA SG 11201610453S A SG11201610453S A SG 11201610453SA SG 11201610453S A SG11201610453S A SG 11201610453SA SG 11201610453S A SG11201610453S A SG 11201610453SA
- Authority
- SG
- Singapore
- Prior art keywords
- virus
- compounds
- pharmaceutical compositions
- inhibiting hepatitis
- hepatitis
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/079386 WO2015184644A1 (en) | 2014-06-06 | 2014-06-06 | Compounds and pharmaceutical compositions for inhibiting hepatitis c virus, and uses thereof |
| PCT/CN2014/092902 WO2015184753A1 (en) | 2014-06-06 | 2014-12-03 | Compounds for inhibiting hepatitis c virus, pharmaceutical compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201610453SA true SG11201610453SA (en) | 2017-02-27 |
Family
ID=54765978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201610453SA SG11201610453SA (en) | 2014-06-06 | 2014-12-03 | Compounds for inhibiting hepatitis c virus, pharmaceutical compositions and uses thereof |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP3153515B1 (en) |
| JP (1) | JP6523440B2 (en) |
| KR (1) | KR102025415B1 (en) |
| AU (1) | AU2014396578C1 (en) |
| BR (1) | BR112016028616B1 (en) |
| CA (1) | CA2951317C (en) |
| DK (1) | DK3153515T3 (en) |
| ES (1) | ES2829920T3 (en) |
| HU (1) | HUE051356T2 (en) |
| IL (1) | IL249403B (en) |
| MX (1) | MX2016016119A (en) |
| MY (1) | MY178515A (en) |
| PE (1) | PE20170266A1 (en) |
| PL (1) | PL3153515T3 (en) |
| PT (1) | PT3153515T (en) |
| RU (1) | RU2671194C2 (en) |
| SG (1) | SG11201610453SA (en) |
| WO (2) | WO2015184644A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109232612A (en) * | 2017-07-11 | 2019-01-18 | 周龙兴 | Inhibit compound, the medical composition and its use of hepatitis C virus |
| CN111118073B (en) * | 2019-12-27 | 2022-02-15 | 宜昌东阳光生化制药有限公司 | Method for synthesizing intermediate of ezetimivir by enzyme method |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101558059B (en) * | 2006-08-11 | 2014-12-03 | 百时美施贵宝公司 | Hepatitis c virus inhibitors |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| BRPI0822323A2 (en) * | 2008-02-13 | 2015-06-16 | Bristol Myers Squibb Co | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |
| US8729077B2 (en) * | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| WO2010096462A1 (en) * | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
| EA020898B1 (en) * | 2009-03-27 | 2015-02-27 | Мерк Шарп Энд Домэ Корп. | Inhibitors of hepatitis c virus replication |
| NZ706236A (en) * | 2009-05-13 | 2016-07-29 | Gilead Pharmasset Llc | Antiviral compounds |
| MX2012006877A (en) * | 2009-12-18 | 2012-08-31 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors. |
| US20130072523A1 (en) * | 2009-12-24 | 2013-03-21 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| CA2800509A1 (en) * | 2010-05-24 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| US8778938B2 (en) * | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011156543A2 (en) * | 2010-06-09 | 2011-12-15 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a protein |
| US20120195857A1 (en) * | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| SG10201509456SA (en) * | 2010-11-17 | 2015-12-30 | Gilead Pharmasset Llc | Antiviral compounds |
| BR112014000563A2 (en) * | 2011-07-09 | 2019-12-10 | Sunshine Lake Pharma Co., Ltd | compound, pharmaceutical composition, and compound use |
| TW201439084A (en) * | 2012-11-29 | 2014-10-16 | Sunshine Lake Pharma Co Ltd | Spiro ring compounds as hepatitis C virus inhibitors and uses thereof |
| CN111116563B (en) * | 2013-06-06 | 2023-07-04 | 上海爱博医药科技有限公司 | Compound for inhibiting hepatitis C virus, pharmaceutical composition and application thereof |
| SG11201608587QA (en) * | 2014-04-15 | 2016-11-29 | Cocrystal Pharma Inc | Potent and selective inhibitors of hepatitis c virus |
-
2014
- 2014-06-06 WO PCT/CN2014/079386 patent/WO2015184644A1/en active Application Filing
- 2014-12-03 ES ES14893934T patent/ES2829920T3/en active Active
- 2014-12-03 PL PL14893934T patent/PL3153515T3/en unknown
- 2014-12-03 SG SG11201610453SA patent/SG11201610453SA/en unknown
- 2014-12-03 BR BR112016028616-2A patent/BR112016028616B1/en active IP Right Grant
- 2014-12-03 CA CA2951317A patent/CA2951317C/en active Active
- 2014-12-03 MY MYPI2016704537A patent/MY178515A/en unknown
- 2014-12-03 EP EP14893934.1A patent/EP3153515B1/en active Active
- 2014-12-03 PT PT148939341T patent/PT3153515T/en unknown
- 2014-12-03 KR KR1020167037073A patent/KR102025415B1/en active IP Right Grant
- 2014-12-03 AU AU2014396578A patent/AU2014396578C1/en active Active
- 2014-12-03 HU HUE14893934A patent/HUE051356T2/en unknown
- 2014-12-03 DK DK14893934.1T patent/DK3153515T3/en active
- 2014-12-03 WO PCT/CN2014/092902 patent/WO2015184753A1/en active Application Filing
- 2014-12-03 RU RU2016151193A patent/RU2671194C2/en active
- 2014-12-03 JP JP2017516017A patent/JP6523440B2/en active Active
- 2014-12-03 PE PE2016002553A patent/PE20170266A1/en unknown
- 2014-12-03 MX MX2016016119A patent/MX2016016119A/en active IP Right Grant
-
2016
- 2016-12-06 IL IL249403A patent/IL249403B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP3153515A1 (en) | 2017-04-12 |
| EP3153515B1 (en) | 2020-08-12 |
| PE20170266A1 (en) | 2017-04-14 |
| KR20170005382A (en) | 2017-01-12 |
| RU2016151193A (en) | 2018-07-17 |
| JP6523440B2 (en) | 2019-05-29 |
| AU2014396578C1 (en) | 2019-04-11 |
| WO2015184753A1 (en) | 2015-12-10 |
| PL3153515T3 (en) | 2021-03-08 |
| AU2014396578A1 (en) | 2017-01-19 |
| JP2017521484A (en) | 2017-08-03 |
| HUE051356T2 (en) | 2021-03-01 |
| IL249403B (en) | 2021-01-31 |
| KR102025415B1 (en) | 2019-09-25 |
| MX2016016119A (en) | 2017-03-28 |
| IL249403A0 (en) | 2017-02-28 |
| BR112016028616B1 (en) | 2021-10-05 |
| EP3153515A4 (en) | 2018-07-25 |
| BR112016028616A2 (en) | 2017-08-22 |
| RU2671194C2 (en) | 2018-10-30 |
| DK3153515T3 (en) | 2020-11-09 |
| CA2951317C (en) | 2019-10-01 |
| MY178515A (en) | 2020-10-15 |
| AU2014396578B2 (en) | 2018-11-22 |
| WO2015184644A1 (en) | 2015-12-10 |
| ES2829920T3 (en) | 2021-06-02 |
| BR112016028616A8 (en) | 2021-07-20 |
| CA2951317A1 (en) | 2015-12-10 |
| RU2016151193A3 (en) | 2018-07-17 |
| PT3153515T (en) | 2020-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276695B (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| IL247062A0 (en) | Heterocyclic compounds , their preparation and compositions pharmaceutical containing them | |
| EP3139920A4 (en) | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof | |
| HUE056175T2 (en) | Pharmaceutical compositions, preparation and uses thereof | |
| IL252397A0 (en) | Pharmaceutical composition, preparation and uses thereof | |
| IL248779A0 (en) | Pharmaceutical compositions for treating infectious diseases | |
| IL290114A (en) | Pharmaceutical composition, preparation and uses thereof | |
| PL3229843T3 (en) | Pharmaceutical composition, preparation and uses thereof | |
| HK1250627A1 (en) | Solid pharmaceutical compositions for treating hcv | |
| ZA201703115B (en) | Long acting pharmaceutical compositions for hepatitis c | |
| HK1255203A1 (en) | Solid pharmaceutical compositions for treating hcv | |
| IL255042B (en) | Bolaamphiphilic compounds, compositions and uses thereof | |
| SG11201610453SA (en) | Compounds for inhibiting hepatitis c virus, pharmaceutical compositions and uses thereof | |
| ZA201500995B (en) | Low dose pharmaceutical composition | |
| HK1245775A1 (en) | Salts as hepatitis c virus inhibitors | |
| GB201600380D0 (en) | Modified virus | |
| GB201522013D0 (en) | Virus | |
| GB201516936D0 (en) | Virus | |
| GB201507419D0 (en) | Virus |